Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.
Identifieur interne : 003778 ( Main/Exploration ); précédent : 003777; suivant : 003779Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.
Auteurs : Graeme J. Hankey ; Susanna R. Stevens ; Jonathan P. Piccini ; Yuliya Lokhnygina ; Kenneth W. Mahaffey ; Jonathan L. Halperin ; Manesh R. Patel ; Günter Breithardt ; Daniel E. Singer ; Richard C. Becker ; Scott D. Berkowitz ; John F. Paolini ; Christopher C. Nessel ; Werner Hacke ; Keith A A. Fox ; Robert M. CaliffSource :
- Stroke [ 1524-4628 ] ; 2014.
Descripteurs français
- KwdFr :
- Accident vasculaire cérébral (), Anticoagulants (administration et posologie), Anticoagulants (effets indésirables), Embolie (), Femelle, Fibrillation auriculaire (sang), Fibrillation auriculaire (traitement médicamenteux), Fibrillation auriculaire (épidémiologie), Humains, Hémorragies intracrâniennes (), Hémorragies intracrâniennes (physiopathologie), Hémorragies intracrâniennes (sang), Hémorragies intracrâniennes (épidémiologie), Inhibiteurs du facteur Xa, Morpholines (administration et posologie), Morpholines (effets indésirables), Mâle, Méthode en double aveugle, Population d'origine africaine (ethnologie), Population d'origine asiatique (ethnologie), Rivaroxaban, Résultat thérapeutique, Sujet âgé, Thiophènes (administration et posologie), Thiophènes (effets indésirables), Vitamine K (antagonistes et inhibiteurs), Warfarine (administration et posologie), Warfarine (effets indésirables), Études prospectives.
- MESH :
- administration et posologie : Anticoagulants, Morpholines, Thiophènes, Warfarine.
- antagonistes et inhibiteurs : Vitamine K.
- effets indésirables : Anticoagulants, Morpholines, Thiophènes, Warfarine.
- ethnologie : Population d'origine africaine, Population d'origine asiatique.
- physiopathologie : Hémorragies intracrâniennes.
- sang : Fibrillation auriculaire, Hémorragies intracrâniennes.
- traitement médicamenteux : Fibrillation auriculaire.
- épidémiologie : Fibrillation auriculaire, Hémorragies intracrâniennes.
- Accident vasculaire cérébral, Embolie, Femelle, Humains, Hémorragies intracrâniennes, Inhibiteurs du facteur Xa, Mâle, Méthode en double aveugle, Rivaroxaban, Résultat thérapeutique, Sujet âgé, Études prospectives.
English descriptors
- KwdEn :
- African Continental Ancestry Group (ethnology), Aged, Anticoagulants (administration & dosage), Anticoagulants (adverse effects), Asian Continental Ancestry Group (ethnology), Atrial Fibrillation (blood), Atrial Fibrillation (drug therapy), Atrial Fibrillation (epidemiology), Double-Blind Method, Embolism (prevention & control), Factor Xa Inhibitors, Female, Humans, Intracranial Hemorrhages (blood), Intracranial Hemorrhages (chemically induced), Intracranial Hemorrhages (epidemiology), Intracranial Hemorrhages (physiopathology), Male, Morpholines (administration & dosage), Morpholines (adverse effects), Prospective Studies, Rivaroxaban, Stroke (prevention & control), Thiophenes (administration & dosage), Thiophenes (adverse effects), Treatment Outcome, Vitamin K (antagonists & inhibitors), Warfarin (administration & dosage), Warfarin (adverse effects).
- MESH :
- chemical , administration & dosage : Anticoagulants, Morpholines, Thiophenes, Warfarin.
- chemical , adverse effects : Anticoagulants, Morpholines, Thiophenes, Warfarin.
- chemical , antagonists & inhibitors : Vitamin K.
- blood : Atrial Fibrillation, Intracranial Hemorrhages.
- chemically induced : Intracranial Hemorrhages.
- drug therapy : Atrial Fibrillation.
- epidemiology : Atrial Fibrillation, Intracranial Hemorrhages.
- ethnology : African Continental Ancestry Group, Asian Continental Ancestry Group.
- physiopathology : Intracranial Hemorrhages.
- prevention & control : Embolism, Stroke.
- Aged, Double-Blind Method, Factor Xa Inhibitors, Female, Humans, Male, Prospective Studies, Rivaroxaban, Treatment Outcome.
Abstract
Intracranial hemorrhage (ICH) is a life-threatening complication of anticoagulation.
DOI: 10.1161/STROKEAHA.113.004506
PubMed: 24743444
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003809
- to stream PubMed, to step Curation: 003695
- to stream PubMed, to step Checkpoint: 003695
- to stream Ncbi, to step Merge: 001971
- to stream Ncbi, to step Curation: 001971
- to stream Ncbi, to step Checkpoint: 001971
- to stream Main, to step Merge: 003808
- to stream Main, to step Curation: 003778
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.</title><author><name sortKey="Hankey, Graeme J" sort="Hankey, Graeme J" uniqKey="Hankey G" first="Graeme J" last="Hankey">Graeme J. Hankey</name><affiliation><nlm:affiliation>From the School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Duke Clinical Research Institute (S.R.S., J.P.P., Y.L., M.R.P.) and Duke Translational Medicine Institute (R.M.C.), Duke University Medical Center, Durham, NC; Department of Medicine, Stanford University, CA (K.W.M.); Cardiovascular Institute, Mount Sinai Medical Center, New York (J.L.H.); Department of Cardiovascular Medicine, Hospital of the University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston (D.E.S.); University of Cincinnati College of Medicine, OH (R.C.B.); Department of Global Clinical Development, Bayer HealthCare Pharmaceuticals, Whippany, NJ (S.D.B.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Ruprecht- Karls-University, Heidelberg, Germany (W.H.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Stevens, Susanna R" sort="Stevens, Susanna R" uniqKey="Stevens S" first="Susanna R" last="Stevens">Susanna R. Stevens</name></author><author><name sortKey="Piccini, Jonathan P" sort="Piccini, Jonathan P" uniqKey="Piccini J" first="Jonathan P" last="Piccini">Jonathan P. Piccini</name></author><author><name sortKey="Lokhnygina, Yuliya" sort="Lokhnygina, Yuliya" uniqKey="Lokhnygina Y" first="Yuliya" last="Lokhnygina">Yuliya Lokhnygina</name></author><author><name sortKey="Mahaffey, Kenneth W" sort="Mahaffey, Kenneth W" uniqKey="Mahaffey K" first="Kenneth W" last="Mahaffey">Kenneth W. Mahaffey</name></author><author><name sortKey="Halperin, Jonathan L" sort="Halperin, Jonathan L" uniqKey="Halperin J" first="Jonathan L" last="Halperin">Jonathan L. Halperin</name></author><author><name sortKey="Patel, Manesh R" sort="Patel, Manesh R" uniqKey="Patel M" first="Manesh R" last="Patel">Manesh R. Patel</name></author><author><name sortKey="Breithardt, Gunter" sort="Breithardt, Gunter" uniqKey="Breithardt G" first="Günter" last="Breithardt">Günter Breithardt</name></author><author><name sortKey="Singer, Daniel E" sort="Singer, Daniel E" uniqKey="Singer D" first="Daniel E" last="Singer">Daniel E. Singer</name></author><author><name sortKey="Becker, Richard C" sort="Becker, Richard C" uniqKey="Becker R" first="Richard C" last="Becker">Richard C. Becker</name></author><author><name sortKey="Berkowitz, Scott D" sort="Berkowitz, Scott D" uniqKey="Berkowitz S" first="Scott D" last="Berkowitz">Scott D. Berkowitz</name></author><author><name sortKey="Paolini, John F" sort="Paolini, John F" uniqKey="Paolini J" first="John F" last="Paolini">John F. Paolini</name></author><author><name sortKey="Nessel, Christopher C" sort="Nessel, Christopher C" uniqKey="Nessel C" first="Christopher C" last="Nessel">Christopher C. Nessel</name></author><author><name sortKey="Hacke, Werner" sort="Hacke, Werner" uniqKey="Hacke W" first="Werner" last="Hacke">Werner Hacke</name></author><author><name sortKey="Fox, Keith A A" sort="Fox, Keith A A" uniqKey="Fox K" first="Keith A A" last="Fox">Keith A A. Fox</name></author><author><name sortKey="Califf, Robert M" sort="Califf, Robert M" uniqKey="Califf R" first="Robert M" last="Califf">Robert M. Califf</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24743444</idno><idno type="pmid">24743444</idno><idno type="doi">10.1161/STROKEAHA.113.004506</idno><idno type="wicri:Area/PubMed/Corpus">003809</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003809</idno><idno type="wicri:Area/PubMed/Curation">003695</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003695</idno><idno type="wicri:Area/PubMed/Checkpoint">003695</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003695</idno><idno type="wicri:Area/Ncbi/Merge">001971</idno><idno type="wicri:Area/Ncbi/Curation">001971</idno><idno type="wicri:Area/Ncbi/Checkpoint">001971</idno><idno type="wicri:Area/Main/Merge">003808</idno><idno type="wicri:Area/Main/Curation">003778</idno><idno type="wicri:Area/Main/Exploration">003778</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.</title><author><name sortKey="Hankey, Graeme J" sort="Hankey, Graeme J" uniqKey="Hankey G" first="Graeme J" last="Hankey">Graeme J. Hankey</name><affiliation><nlm:affiliation>From the School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Duke Clinical Research Institute (S.R.S., J.P.P., Y.L., M.R.P.) and Duke Translational Medicine Institute (R.M.C.), Duke University Medical Center, Durham, NC; Department of Medicine, Stanford University, CA (K.W.M.); Cardiovascular Institute, Mount Sinai Medical Center, New York (J.L.H.); Department of Cardiovascular Medicine, Hospital of the University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston (D.E.S.); University of Cincinnati College of Medicine, OH (R.C.B.); Department of Global Clinical Development, Bayer HealthCare Pharmaceuticals, Whippany, NJ (S.D.B.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Ruprecht- Karls-University, Heidelberg, Germany (W.H.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Stevens, Susanna R" sort="Stevens, Susanna R" uniqKey="Stevens S" first="Susanna R" last="Stevens">Susanna R. Stevens</name></author><author><name sortKey="Piccini, Jonathan P" sort="Piccini, Jonathan P" uniqKey="Piccini J" first="Jonathan P" last="Piccini">Jonathan P. Piccini</name></author><author><name sortKey="Lokhnygina, Yuliya" sort="Lokhnygina, Yuliya" uniqKey="Lokhnygina Y" first="Yuliya" last="Lokhnygina">Yuliya Lokhnygina</name></author><author><name sortKey="Mahaffey, Kenneth W" sort="Mahaffey, Kenneth W" uniqKey="Mahaffey K" first="Kenneth W" last="Mahaffey">Kenneth W. Mahaffey</name></author><author><name sortKey="Halperin, Jonathan L" sort="Halperin, Jonathan L" uniqKey="Halperin J" first="Jonathan L" last="Halperin">Jonathan L. Halperin</name></author><author><name sortKey="Patel, Manesh R" sort="Patel, Manesh R" uniqKey="Patel M" first="Manesh R" last="Patel">Manesh R. Patel</name></author><author><name sortKey="Breithardt, Gunter" sort="Breithardt, Gunter" uniqKey="Breithardt G" first="Günter" last="Breithardt">Günter Breithardt</name></author><author><name sortKey="Singer, Daniel E" sort="Singer, Daniel E" uniqKey="Singer D" first="Daniel E" last="Singer">Daniel E. Singer</name></author><author><name sortKey="Becker, Richard C" sort="Becker, Richard C" uniqKey="Becker R" first="Richard C" last="Becker">Richard C. Becker</name></author><author><name sortKey="Berkowitz, Scott D" sort="Berkowitz, Scott D" uniqKey="Berkowitz S" first="Scott D" last="Berkowitz">Scott D. Berkowitz</name></author><author><name sortKey="Paolini, John F" sort="Paolini, John F" uniqKey="Paolini J" first="John F" last="Paolini">John F. Paolini</name></author><author><name sortKey="Nessel, Christopher C" sort="Nessel, Christopher C" uniqKey="Nessel C" first="Christopher C" last="Nessel">Christopher C. Nessel</name></author><author><name sortKey="Hacke, Werner" sort="Hacke, Werner" uniqKey="Hacke W" first="Werner" last="Hacke">Werner Hacke</name></author><author><name sortKey="Fox, Keith A A" sort="Fox, Keith A A" uniqKey="Fox K" first="Keith A A" last="Fox">Keith A A. Fox</name></author><author><name sortKey="Califf, Robert M" sort="Califf, Robert M" uniqKey="Califf R" first="Robert M" last="Califf">Robert M. Califf</name></author></analytic><series><title level="j">Stroke</title><idno type="eISSN">1524-4628</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>African Continental Ancestry Group (ethnology)</term><term>Aged</term><term>Anticoagulants (administration & dosage)</term><term>Anticoagulants (adverse effects)</term><term>Asian Continental Ancestry Group (ethnology)</term><term>Atrial Fibrillation (blood)</term><term>Atrial Fibrillation (drug therapy)</term><term>Atrial Fibrillation (epidemiology)</term><term>Double-Blind Method</term><term>Embolism (prevention & control)</term><term>Factor Xa Inhibitors</term><term>Female</term><term>Humans</term><term>Intracranial Hemorrhages (blood)</term><term>Intracranial Hemorrhages (chemically induced)</term><term>Intracranial Hemorrhages (epidemiology)</term><term>Intracranial Hemorrhages (physiopathology)</term><term>Male</term><term>Morpholines (administration & dosage)</term><term>Morpholines (adverse effects)</term><term>Prospective Studies</term><term>Rivaroxaban</term><term>Stroke (prevention & control)</term><term>Thiophenes (administration & dosage)</term><term>Thiophenes (adverse effects)</term><term>Treatment Outcome</term><term>Vitamin K (antagonists & inhibitors)</term><term>Warfarin (administration & dosage)</term><term>Warfarin (adverse effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Accident vasculaire cérébral ()</term><term>Anticoagulants (administration et posologie)</term><term>Anticoagulants (effets indésirables)</term><term>Embolie ()</term><term>Femelle</term><term>Fibrillation auriculaire (sang)</term><term>Fibrillation auriculaire (traitement médicamenteux)</term><term>Fibrillation auriculaire (épidémiologie)</term><term>Humains</term><term>Hémorragies intracrâniennes ()</term><term>Hémorragies intracrâniennes (physiopathologie)</term><term>Hémorragies intracrâniennes (sang)</term><term>Hémorragies intracrâniennes (épidémiologie)</term><term>Inhibiteurs du facteur Xa</term><term>Morpholines (administration et posologie)</term><term>Morpholines (effets indésirables)</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Population d'origine africaine (ethnologie)</term><term>Population d'origine asiatique (ethnologie)</term><term>Rivaroxaban</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Thiophènes (administration et posologie)</term><term>Thiophènes (effets indésirables)</term><term>Vitamine K (antagonistes et inhibiteurs)</term><term>Warfarine (administration et posologie)</term><term>Warfarine (effets indésirables)</term><term>Études prospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anticoagulants</term><term>Morpholines</term><term>Thiophenes</term><term>Warfarin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anticoagulants</term><term>Morpholines</term><term>Thiophenes</term><term>Warfarin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Vitamin K</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticoagulants</term><term>Morpholines</term><term>Thiophènes</term><term>Warfarine</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Vitamine K</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Atrial Fibrillation</term><term>Intracranial Hemorrhages</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Intracranial Hemorrhages</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Atrial Fibrillation</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticoagulants</term><term>Morpholines</term><term>Thiophènes</term><term>Warfarine</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Atrial Fibrillation</term><term>Intracranial Hemorrhages</term></keywords><keywords scheme="MESH" qualifier="ethnologie" xml:lang="fr"><term>Population d'origine africaine</term><term>Population d'origine asiatique</term></keywords><keywords scheme="MESH" qualifier="ethnology" xml:lang="en"><term>African Continental Ancestry Group</term><term>Asian Continental Ancestry Group</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Hémorragies intracrâniennes</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Intracranial Hemorrhages</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Embolism</term><term>Stroke</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Fibrillation auriculaire</term><term>Hémorragies intracrâniennes</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Fibrillation auriculaire</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Fibrillation auriculaire</term><term>Hémorragies intracrâniennes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Double-Blind Method</term><term>Factor Xa Inhibitors</term><term>Female</term><term>Humans</term><term>Male</term><term>Prospective Studies</term><term>Rivaroxaban</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Accident vasculaire cérébral</term><term>Embolie</term><term>Femelle</term><term>Humains</term><term>Hémorragies intracrâniennes</term><term>Inhibiteurs du facteur Xa</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Rivaroxaban</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Études prospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Intracranial hemorrhage (ICH) is a life-threatening complication of anticoagulation.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Becker, Richard C" sort="Becker, Richard C" uniqKey="Becker R" first="Richard C" last="Becker">Richard C. Becker</name><name sortKey="Berkowitz, Scott D" sort="Berkowitz, Scott D" uniqKey="Berkowitz S" first="Scott D" last="Berkowitz">Scott D. Berkowitz</name><name sortKey="Breithardt, Gunter" sort="Breithardt, Gunter" uniqKey="Breithardt G" first="Günter" last="Breithardt">Günter Breithardt</name><name sortKey="Califf, Robert M" sort="Califf, Robert M" uniqKey="Califf R" first="Robert M" last="Califf">Robert M. Califf</name><name sortKey="Fox, Keith A A" sort="Fox, Keith A A" uniqKey="Fox K" first="Keith A A" last="Fox">Keith A A. Fox</name><name sortKey="Hacke, Werner" sort="Hacke, Werner" uniqKey="Hacke W" first="Werner" last="Hacke">Werner Hacke</name><name sortKey="Halperin, Jonathan L" sort="Halperin, Jonathan L" uniqKey="Halperin J" first="Jonathan L" last="Halperin">Jonathan L. Halperin</name><name sortKey="Hankey, Graeme J" sort="Hankey, Graeme J" uniqKey="Hankey G" first="Graeme J" last="Hankey">Graeme J. Hankey</name><name sortKey="Lokhnygina, Yuliya" sort="Lokhnygina, Yuliya" uniqKey="Lokhnygina Y" first="Yuliya" last="Lokhnygina">Yuliya Lokhnygina</name><name sortKey="Mahaffey, Kenneth W" sort="Mahaffey, Kenneth W" uniqKey="Mahaffey K" first="Kenneth W" last="Mahaffey">Kenneth W. Mahaffey</name><name sortKey="Nessel, Christopher C" sort="Nessel, Christopher C" uniqKey="Nessel C" first="Christopher C" last="Nessel">Christopher C. Nessel</name><name sortKey="Paolini, John F" sort="Paolini, John F" uniqKey="Paolini J" first="John F" last="Paolini">John F. Paolini</name><name sortKey="Patel, Manesh R" sort="Patel, Manesh R" uniqKey="Patel M" first="Manesh R" last="Patel">Manesh R. Patel</name><name sortKey="Piccini, Jonathan P" sort="Piccini, Jonathan P" uniqKey="Piccini J" first="Jonathan P" last="Piccini">Jonathan P. Piccini</name><name sortKey="Singer, Daniel E" sort="Singer, Daniel E" uniqKey="Singer D" first="Daniel E" last="Singer">Daniel E. Singer</name><name sortKey="Stevens, Susanna R" sort="Stevens, Susanna R" uniqKey="Stevens S" first="Susanna R" last="Stevens">Susanna R. Stevens</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003778 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003778 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24743444
|texte= Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24743444" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |